[HTML][HTML]Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
GD Kamphaus, PCColorado, DJ Panka… - Journal of Biological …, 2000 - ASBMB
We isolated and identified an endogenous 24-kDa human basement membrane-derived
inhibitor of angiogenesis and tumor growth, termed canstatin. Canstatin, a fragment of the α2 …
inhibitor of angiogenesis and tumor growth, termed canstatin. Canstatin, a fragment of the α2 …
Anti-angiogenic cues from vascular basement membrane collagen
PCColorado, A Torre, G Kamphaus, Y Maeshima… - Cancer research, 2000 - AACR
Vascular basement membrane is an important structural component of blood vessels and
has been shown to interact with and modulate vascular endothelial behavior during …
has been shown to interact with and modulate vascular endothelial behavior during …
[HTML][HTML]Distinct antitumor properties of a type IV collagen domain derived from basement membrane
Y Maeshima, PCColorado, A Torre… - Journal of Biological …, 2000 - ASBMB
Vascular basement membrane is an important structural component of blood vessels.
During angiogenesis this membrane undergoes many alterations and these changes are …
During angiogenesis this membrane undergoes many alterations and these changes are …
Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation
M Zeisberg, G Bonner, Y Maeshima, PColorado… - The American journal of …, 2001 - Elsevier
Type IV collagen is a major component of basement membranes and it provides structural
and functional support to various cell types. Type IV collagen exists in a highly complex …
and functional support to various cell types. Type IV collagen exists in a highly complex …
[HTML][HTML]Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties
Y Maeshima, PCColorado,R Kalluri- Journal of Biological Chemistry, 2000 - ASBMB
Vascular basement membrane is an important regulator of angiogenesis and undergoes
many alterations during angiogenesis and these changes are speculated to influence …
many alterations during angiogenesis and these changes are speculated to influence …
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)
…, A Fritsch, N Davie, PColorado… - European …, 2015 - Eur Respiratory Soc
Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of inoperable
and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). In the …
and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). In the …
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label …
…,E Mayer, T Pulido, C Wang, PColorado… - The lancet Respiratory …, 2016 - Elsevier
Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating,
and life-threatening disease. We investigated associations between markers of disease …
and life-threatening disease. We investigated associations between markers of disease …
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
…,CD Vizza, MK Chang, PColorado2017 -欧盟欧洲……,r Respiratory Soc
A proportion of pulmonary arterial hypertension (PAH) patients do not reach treatment goals
with phosphodiesterase-5 inhibitors (PDE5i). RESPITE investigated the safety, feasibility …
with phosphodiesterase-5 inhibitors (PDE5i). RESPITE investigated the safety, feasibility …
Characterization of the anti-angiogenic properties of arresten, an α1β1 integrin-dependent collagen-derived tumor suppressor
P Nyberg, L Xie, H Sugimoto, PColorado… - Experimental cell …, 2008 - Elsevier
Physiological and pathological turnover of basement membranes liberates biologically active
cryptic molecules. Several collagen-derived fragments possess anti-angiogenic activity. …
cryptic molecules. Several collagen-derived fragments possess anti-angiogenic activity. …
[HTML][HTML]Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: results from a phase II long-term extension study
…, G Stähler, J Behr, R Ewert, M Fletcher, PColorado… - Respiratory …, 2017 - Elsevier
Background Riociguat was well tolerated and improved exercise and functional capacity in
patients with pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic …
patients with pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic …